Boston, January 25, 2017 – Cytonome/ST, LLC announces it has signed the first application specific agreement to license its proprietary GigaSortTM Technology for commercial scale cell therapy production. A premier pharmaceutical company has signed on for rights to use the technology for their explicit disease indication. They will manufacture a critical cell therapy to address one of the major diseases afflicting aging populations globally.
The GigaSort Platform is an application specific laser-based cell sorter that allows the identification, characterization, and isolation of highly purified cell populations. [Read more…]